SEC Form 4 · accession 0000904454-16-001322
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian H Dovey
Director
Period of report
Jul 12, 2016
Accepted (ET)
Jul 14, 2016 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.02 | Jul 12, 2016 | A | 15,000 | A | — | Jul 11, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F11/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 12, 2016, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date.